Jenburkt Pharmaceuticals enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast closeFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5.65.67.44.13.7
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.00.02.00.02.4
−5.6−5.6−5.4−4.1−1.2
Reference items — trailing FY values
169169152142137
40.240.237.230.527.7
40.240.237.230.527.7
26.526.527.98.117.1
26.526.527.98.117.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

JENBURPH₹875.95

Jenburkt Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current
last close
- Cash, Equiv & ST Investments3.74.17.45.65.6
+ Total Debt2.40.02.00.00.0
Net Debt (memo)-1.2-4.1-5.4-5.6-5.6
Reference Items — Trailing FY Values
Sales136.7142.0151.7168.7168.7
EBITDA27.730.537.240.240.2
EBIT27.730.537.240.240.2
Operating Cash Flow17.18.127.926.526.5
Free Cash Flow17.18.127.926.526.5
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.